So far, the underlying mechanisms behind the cardiovascular protection observed in clinical trials of SGLT2 inhibitors remain incompletely understood and there is a great scientific interest in potential pathways linking SGLT2 to diabetes and cardiovascular disease. This evidence concerns the gene SLC5A2 and cardiovascular disorder.